Active substanceDecitabineDecitabine
Similar drugsTo uncover
  • Dacogen
    concentratelyophilizatesolution d / infusion 
  • Dosage form: & nbsp
    lyophilizate for the preparation of concentrate for the preparation of a solution for infusions
    Composition:
    Active substance: decitabine 50 mg;
    Excipients: potassium dihydrogen phosphate - 68 mg, sodium hydroxide - 11.6 mg. If it is necessary to adjust the pH of the lyophilisate, 1M sodium hydroxide q.s. or a 1M solution of hydrochloric acid q.s.
    Description:Compact or powdery white mass.
    Pharmacotherapeutic group:Antitumour agent, antimetabolite
    ATX: & nbsp

    L.01.B.C   Analogs of pyrimidine

    Pharmacodynamics:Decitabine (5-aza-2'-deoxycytidine) is an analogue of the cytidine nucleoside, which in small doses selectively inhibits the activity of DNA methyltransferase, which leads to hypomethylation of the promoters of suppressor genes, their reactivation, induction of cell differentiation or aging of cells, followed by their programmed death .
    Pharmacokinetics:

    Population pharmacokinetic parameters of decitabine were obtained in three studies in which a 5-day dosing regimen (20 mg / m2 for 1 hour, 5 days, every 4 weeks) and in a study that used a 3-day dosing regimen (15 mg / m2 for 3 hours, every 8 hours, 3 days, every 6 weeks) at patients with acute myeloid leukemia (OMJI) and myelodysplastic syndrome (MDS). With a five-day dosing regimen, the pharmacokinetic parameters of decitabine were evaluated on the fifth day of the first treatment cycle. The total dose per treatment cycle was 100 mg / m2. With a three-day dosing regimen, the pharmacokinetic parameters of decitabine were evaluated every day in the first treatment cycle, after the first dose. The total dose for the treatment cycle was 135 mg / m2.

    Distribution:

    The pharmacokinetics of decitabine after intravenous infusion for 1 h (5-day regimen) or 3 h (3-day regimen) was described by a linear two-chamber model characterized by rapid removal of the drug from the central chamber and a relatively slow distribution from the peripheral chamber. For the average patient (weight 70 kg / body surface 1.73 m2), the pharmacokinetic parameters of decitabine are given below, in Table 1.

    Table 1. Summary of population pharmacokinetic parameters for the average patient (5-day and 3-day regimens)

    5-day mode

    3-Day Mode

    Parameter

    Expected value

    95 % CI

    Expected value

    95 % CI

    FROM max

    ng / ml)

    107

    88,5-129

    42,3

    35,2-50,6

    AUCcum(ng.v / ml)

    580

    480-695

    1161

    972-1390

    t1/2(mines)

    68,2

    54,2-79,6

    67,5

    53,6-78,8

    Vdss (L)

    116

    84,1-153

    49,6

    34,9-65,5

    CL (l / h)

    298

    249-359

    201

    168-241

    AUC= the area under the concentration-time curve in plasma, CL= total clearance in the body, Cmax = the maximum observed concentration, t1/2= the final elimination half-life, Vdss = average volume of distribution in equilibrium

    Decitabine demonstrates a linear pharmacokinetics, after intravenous infusion the equilibrium concentration is reached within 0.5 hours. The simulation showed that the pharmacokinetic parameters did not depend on time (i.e., did not vary from cycle to cycle), and no cumulation was observed with these dosing regimes. Decitabine to an insignificant extent (<1%) binds to plasma proteins. Vdss decitabine in cancer patients is an indicator of the distribution of the drug in peripheral tissues. There was no evidence of dependence of pharmacokinetics on age, creatinine clearance, total bilirubin, or disease stage.

    Metabolism: in cages decitabine is sequentially phosphorylated with phosphokinases to the corresponding triphosphate, which is inserted by DNA polymerase into DNA.Taking into account the data on the metabolism obtained in vitro, the results of a mass-balance study indicate that cytochrome P450 does not participate in the metabolism of decitabine. The main way of metabolism of decitabine is most likely associated with deamination of cytidine deaminase in the liver, kidneys, intestinal epithelium and in the blood. The results of mass-balance research in humans showed that unchanged decitabine in plasma is approximately 2.4%. The major circulating metabolites of decitabine are considered pharmacologically inactive.

    The presence of these metabolites in the urine together with high overall clearance and a slight excretion of unchanged substance with urine (~ 4% of the administered dose) indicates a significant metabolism of the substance in vivo. In addition, the data received in vitro show that decitabine is a poor substrate for P-glycoprotein (P-gp).

    Excretion: The average clearance of the substance from blood plasma after intravenous administration to oncological patients was> 200 l / h with a moderate individual variation (Coefficient of variation (KB) approximately 50%). In an unchanged form, apparently, only a small part of the introduced decitabine is excreted.

    Results of the mass-balance study with radioactive 14C-decitabine in cancer patients showed that 90% of the administered dose of decitabine (4% of the unchanged drug) is excreted in the urine.

    Special categories of patients

    The pharmacokinetics of decitabine in groups of patients with impaired renal and hepatic function in special studies has not been studied, no pharmacokinetic dependency studies have been conducted on the sex, age and race of the patient.

    Elderly patients

    Population pharmacokinetic analysis showed that the pharmacokinetics of decitabine is independent of age (a range of 40 to 87 years, an average value of 70 years) has been studied.

    Floor

    Population pharmacokinetic analysis of decitabine did not reveal any clinically significant differences between men and women.

    Race

    Most of the patients participating in the studies were Caucasians. However, group pharmacokinetic analysis indicated that the race had no apparent effect on the pharmacokinetics of decitabine.

    Liver failure

    Pharmacokinetic analysis of decitabine in patients with hepatic insufficiency was not separately performed.Results of mass-balance research in humans and experiments in vitro, mentioned above indicate that isoenzymes CYP450 hardly participate in the metabolism of decitabine. In addition, limited data obtained from population pharmacokinetic analysis indicate a lack of reliable pharmacokinetic parameters dependence on the level of total bilirubin, despite a wide range of bilirubin levels. Consequently, it is unlikely that the excretion of decitabine will change in patients with hepatic insufficiency.

    Renal insufficiency

    Pharmacokinetic analysis of decitabine in patients with renal insufficiency was not carried out separately. Population pharmacokinetic analysis of limited available data on decitabine does not indicate a reliable dependence of pharmacokinetic parameters on creatinine clearance, an index of kidney function. Consequently, it is unlikely that the excretion of decitabine will change in patients with renal insufficiency.

    Indications:
    - treatment of myelodysplastic syndrome (MDS) of all types in previously treated and untreated adult patients.
    - treatment of newly diagnosed primary or secondary (according to WHO classification) of acute myeloid leukemia in adult patients aged 65 years and older.
    Contraindications:
    - Known hypersensitivity to decitabine or any component of the drug.
    - Pregnancy and the period of breastfeeding.
    - Children under 18 years of age (efficacy and safety not established).
    Carefully:
    Hepatic failure.
    Severe kidney failure.
    Severe heart disease (including heart disease with congestive heart failure in history, heart disease in the decompensation stage).
    Myelosuppression.
    Pregnancy and lactation:
    Pregnancy
    Women who are capable of giving birth should be recommended to use effective contraception and avoid pregnancy during treatment with decitabine (including treatment with decitabine of a sexual partner). Unknown period of time after the end of treatment with Dacogen, safe for pregnancy. Data on the use of Dacogen in pregnant women are absent. Studies have shown that decitabine has a teratogenic effect in rats and mice.The potential risk in humans is unknown. Taking the drug Dacogen during pregnancy is contraindicated. If pregnancy develops during the treatment period, the drug should be immediately discontinued. Patients of childbearing age should be advised to seek advice on cryopreservation of eggs before starting treatment with Dacogen.
    Breast-feeding
    It is not known whether decitabine or its metabolites with breast milk. Dacogen during breastfeeding is contraindicated, so if you need to use Dacogen, breastfeeding should be discontinued.
    Dosing and Administration:

    Dakogen should be administered under the supervision of a doctor who has experience in the use of chemotherapy drugs.

    The dacogen is administered by intravenous infusion. A central venous catheter is not required. Recommended 2 modes of dosing Dakogen: 5-day treatment OMJI and 3 or 5-day treatment for MDS. In both regimens, the recommended duration of treatment is at least 4 cycles, but more than 4 cycles may be required to achieve a response. In patients with OMJI the mean response time (complete response or complete response with incomplete platelet recovery) was 4.3 months. In patients with MDS with a 5-day dosing regimen, the average response was 3.5 cycles, and for 3 days - after 3 cycles. Treatment can continue as long as the response or stabilization of the disease persists, i.e. there is no obvious progression of the disease. If, after 4 cycles of treatment, the hematologic indices (platelet count and absolute neutrophil count) do not return to the baseline level, and also in case of progression of the disease (increase in the number of blast cells in the bone marrow or peripheral blood), the patient can be regarded as not responding to treatment, and Alternative therapy should be considered.

    Premedication for the prevention of nausea and vomiting is usually not recommended, although it can be carried out if necessary.

    Dosage regimen for AML

    Dacogen is administered daily for 5 consecutive days at a dose of 20 mg / m2 surfaces

    body by 1-hour intravenous infusion (ie, only 5 doses per treatment cycle). This cycle is repeated every 4 weeks, depending on the response to therapy and the manifestations of toxicity in the patient. The total daily dose should not exceed 20 mg / m2, and the total dose per cycle should not exceed 100 mg / m2. If you miss a regular dose, you should enter it as soon as possible. This treatment regimen can be performed on an outpatient basis.

    Dosing regimen with MDS

    Five-day dosing regimen

    Dacogen is administered daily for 5 consecutive days at a dose of 20 mg / m2 body surface by 1-hour intravenous infusion (ie, only 5 doses per treatment cycle). This cycle is repeated every 4 weeks, depending on the response to therapy and the manifestations of toxicity in the patient. The total daily dose should not exceed 20 mg / m2, and the total dose per cycle should not exceed 100 mg / m2. If you miss a regular dose, you should enter it as soon as possible. This treatment regimen can be performed on an outpatient basis.

    Three-day dosing regimen

    Dacogen is used at a dose of 15 mg / m body surface by continuous 3-hour intravenous infusion every 8 hours for 3 days (ie, only 9 doses per treatment cycle). This cycle is repeated approximately every 6 weeks, depending on the response to therapy and the manifestations of toxicity in the patient. The total daily dose should not exceed 45 mg / m2, and the total dose per cycle is 135 mg / m2. If the next dose is missed, treatment should be resumed as soon as possible.

    Treatment of myelosuppression and complications associated with it

    Myelosuppression and undesirable phenomena associated with myelosuppression (thrombocytopenia, anemia, neutropenia and febrile neutropenia) are often found in previously treated and untreated patients with OMJI and MDS. Complications of myelosuppression include infection and bleeding. Treatment can be modified in patients who developed myelosuppression and the complications associated with it, described below:

    With AML

    Treatment can be delayed at the discretion of the attending physician if the patient experiences complications associated with myelosuppression described below:

    - Febrile neutropenia (fever >38.5 ° C and the absolute number of neutrophils <1000 / μl)

    - An active viral, bacterial or fungal infection (i.e., requiring intravenous anti-infective or intensive maintenance therapy)

    - Bleeding (gastrointestinal, urogenital, pulmonary with a platelet count <25,000 / μl or in the central nervous system)

    Treatment with Dakogen can be resumed after an improvement or stabilization of the condition with adequate treatment (anti-infective therapy, transfusion or the introduction of colony-stimulating factors).Decrease in the dose of Dacogen is not recommended.

    With MDS

    Five-day dosing regimen

    It is not recommended to reduce the dose to optimize therapy. The dose should be adjusted as described below:

    - Correction of dose in the first 3 cycles

    In the first cycles of treatment, cytopenias of grade 3 and 4 are often observed, which may not be a sign of progression of MDS. Cytopenia, which existed before the start of treatment, can persist until the end of the third cycle of treatment.

    During the first three cycles, in order to achieve the best possible benefit in conditions of moderate neutropenia (absolute neutrophil count <1000 / μl), every effort should be made to administer a complete dose of the preparation at standard intervals between cycles. Before the recovery of granulocyte counts above 500 / μL, concomitant antibiotic therapy can be performed in accordance with the clinical practice. At the same time, the doctor should also consider the need for early application of colony-stimulating factors for the prevention or treatment of infections in MDS patients.

    Similarly, to achieve the best effect in conditions of moderate thrombocytopenia (platelet count <25,000 / μL),make every effort to introduce a full dose of the drug with standard intervals between cycles. In cases of bleeding, concomitant transfusion of platelet mass can be performed.

    - Correction of dose after 3 cycles

    The introduction of the next dose should be postponed with the development of the next toxicity, estimated at least as possibly related to the use of the drug:

    - Severe complications of myelosuppression (infection and / or bleeding that do not stop with adequate therapy)

    - Prolonged myelosuppression, defined as a hypocellular marrow (cells not more than 5% of the norm) without signs of progression for 6 or more weeks after the start of the treatment cycle.

    If recovery is required (absolute neutrophil count> 1000 / μL, platelet count> 50,000 / μL), it takes more than 8 weeks, then treatment is stopped and within 7 days after the end of week 8 bone marrow is analyzed for detection progression of the disease. If the patient has received at least 6 cycles of treatment, and he has a favorable effect, then in the absence of progression, at the discretion of the doctor, a delay of the next cycle for more than 8 weeks is allowed.

    Three-day dosing regimen

    - Correction of dose in the first 3 cycles

    In the first cycles of treatment, cytopenias of grade 3 and 4 are often observed, which may not be a sign of progression of MDS. Cytopenia, which existed before the beginning of treatment, may not be weakened until the end of the third cycle of treatment.

    During the first three cycles, in order to achieve the best possible benefit in conditions of moderate neutropenia (absolute neutrophil count <1000 / μl), every effort should be made to administer a complete dose of the preparation at standard intervals between cycles. Before the recovery of granulocyte counts above 500 / μl, concomitant antibacterial prophylaxis can be carried out in accordance with the practice of the clinic. At the same time, the doctor should also consider the need for early application of colony-stimulating factors for the prevention or treatment of infections in MDS patients.

    Similarly, to achieve the best effect in conditions of moderate thrombocytopenia (platelet count <25,000 / μL), every effort should be made to administer the complete dose of the drug at standard intervals between cycles. In cases of bleeding, concomitant transfusion of platelet mass can be performed.

    - Correction of dose after the 3rd cycle

    If the recovery of hematological parameters (absolute neutrophil count> 1000 / μL, platelet count> 50000 / μL) after the previous cycle of Dakogen administration takes more than 6 weeks, and the remaining cytopenia is regarded as associated with the use of the drug, the beginning of the next cycle is postponed and the dose is reduced by the following algorithm.

    Any dose reduction is maintained until the end of treatment, i.e. back dose can not be increased.

    - If the recovery takes more than 6 weeks, but less than 8 weeks, the beginning of the next cycle is postponed for up to 2 weeks, and the dose in the next cycle is reduced to

    11 mg / m2 every 8 hours (33 mg / m2/ day, 99 mg / m2/cycle).

    If the recovery takes more than 8 weeks, but less than 10 weeks, the start of the next cycle is delayed for a further 2 weeks, and the dose in the next cycle is reduced to 11 mg / m2 every 8 hours (33 mg / m2/ day, 99 mg / m2/cycle). In subsequent cycles, the dose is maintained depending on the clinical indications.

    If the recovery takes more than 10 weeks, the drug is discontinued and the bone marrow is analyzed for 7 days after the end of the 10th week to determine the progression of the disease.If the patient has received at least 6 cycles of treatment, and he has a favorable effect, then in the absence of progression at the discretion of the doctor, a delay of the next cycle for more than 10 weeks is allowed.

    Special patient groups:

    Children: Safety and efficacy in children not established.

    Liver failure: Studies in patients with hepatic insufficiency have not been conducted. Need for dose adjustment in patients with hepatic impairment

    not evaluated. If the liver function worsens, patients should be carefully monitored (see sections "Special instructions" and "Pharmacological properties").

    - Renal insufficiency: Studies in patients with renal insufficiency have not been carried out, however, according to clinical studies, patients with mild to moderate renal failure do not require dose adjustment. Clinical studies involving patients with severe renal failure have not been conducted.

    Preparation and handling of the drug

    The contents of the vial are for single use only.Avoid contact with the skin and use protective gloves. Standard procedures for handling antitumor drugs should be followed. Dacogen under aseptic conditions is dissolved in 10 ml of sterile water for injection. After dissolution, each 1 ml of the resulting solution contains about 5.0 mg of decitabine at a pH of 6.7-7.3.

    Immediately after preparation, the preparation is diluted with infusion solutions (0.9% sodium chloride solution or 5% dextrose solution) to a final concentration of 0.1-1.0 mg / ml.

    If the solution is not supposed to be injected within 15 minutes after preparation, the lyophilizate is dissolved in aseptic conditions in 10 ml of sterile water for injection and then diluted with a cold infusional solution (2-8 ° C) and stored at 2-8 ° C, no more than 4 hours.

    Side effects:

    The following undesirable phenomena occur when the drug is used

    Dacogen in more than 5% of patients with myelodysplastic syndrome.

    From the hematopoietic system: neutropenia, thrombocytopenia, anemia, febrile neutropenia, leukopenia, pancytopenia, lymphadenopathy, thrombocythemia.

    From the cardiovascular system: lowering blood pressure, increasing blood pressure, congestive heart failure, tachycardia, petechiae, bruises, heart murmurs.

    On the part of the respiratory system: cough, shortness of breath, hypoxia, pleural effusion, pulmonary edema, pharyngitis, postnatal congestion, nosebleeds, sinus congestion, wheezing (including wet) in the lungs, pain in the larynx and pharynx.

    On the part of the digestive system: Nausea, vomiting, anorexia, constipation, diarrhea, abdominal pain, stomatitis, gingival hemorrhage, dyspepsia, ascites, dysphagia, flatulence, gastroesophageal reflux, glossidia (pain in the tongue), exacerbation of hemorrhoids, toothache, oral pain, stool, ulceration of the tongue, ulceration of the lips, damage to the soft tissues of the oral cavity, pain in the upper abdomen.

    From the urinary system: dysuria, frequent urge to urinate.

    From the immune system: hypersensitivity, drug hypersensitivity, anaphylactic reactions, anaphylactic shock, anaphylactoid reactions, anaphylactoid shock.

    From the central and peripheral nervous system: headache, dizziness, hypoesthesia, insomnia, confusion, anxiety, depression.

    From the side of the organ of vision: blurred vision.

    From the organ of hearing: earache.

    From the skin and subcutaneous tissues: ecchymosis, rash, erythema, pruritus, urticaria, dry skin, alopecia, night sweats, petechiae, skin lesions.

    From the musculoskeletal system: arthralgia, myalgia, pain in the extremities, back pain, pain in the chest, bone pain, discomfort in the bones and muscles, muscle spasms, muscle weakness.

    Local reactions: erythema, edema, pain.

    Metabolic disorders: Hyperglycemia, hypoalbuminemia, hypomagnesemia, hypokalemia, hyperkalemia, hyponatremia, dehydration.

    Changes in laboratory indicators: hyperbilirubinemia, lowering the concentration of bilirubin in the blood, increasing the activity of aspartate aminotransferase (ast), increasing the activity of alkaline phosphatase, increasing the activity of lactate dehydrogenase, increasing the urea concentration in the blood, reducing the concentration of serum albumin and total protein, increasing or decreasing the concentration of bicarbonates, reducing the concentration of chloride in the blood.

    Other: fever, chills, a feeling of malaise, inhibition, pain in the chest, chest discomfort, mucosal inflammation, intermittent fever, crepitus, pain at the site of the catheter, soreness, reaction to transfusion, scratches, bruise, fatigue, asthenia , decreased appetite, edema (including facial swelling, edema at the site of insertion of the catheter), peripheral edema, attachment of secondary infections (pneumonia, phlegmon, candidal infections, including candidiasis of the oral cavity, urinary tract infections , staphylococcal infections, sinusitis, bacteremia, dental abscess, upper respiratory infections, infections associated with catheter, sepsis (including fatal), septic shock, acute febrile fibril dermatosis (Sweet syndrome), weight loss. The most common adverse reactions for both the 3-day and 5-day dosing regimens were myelosuppression and complications associated with it.The following are side reactions classified by organs and frequency for acute myeloid leukemia (very frequent - >1/10, frequent from >1/100 to <1/10 and infrequent from >1/1000 to <1/100).

    Infections: Often - pneumonia *, urinary tract infections *, other infections (all viral, bacterial, fungal infections, including fatal) *1; often: septic shock *, sepsis *, sinusitis.

    From the hematopoietic system: Often - febrile neutropenia *, neutropenia *, thrombocytopenia * (including bleeding associated with thrombocytopenia, including fatal), anemia, leukopenia; often - pancytopenia *, gastrointestinal bleeding, intracerebral hemorrhage.

    On the part of the respiratory system: Often - nose bleed.

    From the side of the digestive system: Often - diarrhea, vomiting, stomatitis, nausea.

    From the immune system: often hypersensitivity, including anaphylactic reactions (hypersensitivity, drug hypersensitivity, anaphylactic shock, anaphylactoid reactions, anaphylactoid shock).

    From the central and peripheral nervous system: Often - headache.

    From the skin and subcutaneous tissues: infrequently - Acute febrile neutrophilic dermatosis (Sweet syndrome).

    Common violations: Often - Pyrexia.

    * - Including fatalities

    1 - excluding pneumonia, urinary tract infections, sepsis, septic shock and sinusitis

    Overdose:
    There have been no cases of direct overdose of decitabia, and there is no specific antidote. However, in early clinical studies, the literature has described the enhancement of myelosuppression, including prolonged neutropenia and thrombocytopenia when doses 20 times higher than those currently recommended. Toxicity, most likely, will be manifested by pronounced dose-dependent undesirable phenomena, mainly myelosuppression (see section "Side effect"). In case of an overdose, support therapy is provided.
    Interaction:

    There were no special clinical studies on the interaction of decitabine with other drugs.

    Decitabine-induced myelosuppression may be exacerbated by other antitumor drugs.

    There is a potential for interaction between the Dakogen preparation and other drugs activated by sequential phosphorylation (by activation of intracellular phosphokinase) and / or by metabolizing enzymes involved in the inactivation of decitabine (for example,cytidine deaminase). Such medications should be administered with caution in Dakogen therapy.

    The effect of concomitant therapy on decitabine:

    Pharmacodynamic drug interactions associated with isoenzymes CYP 450 are unlikely, since the exchange of decitabine occurs through oxidative deamination.

    Since the binding of decitabine to blood plasma proteins in vitro extremely low (<1%), then It is unlikely that he will be ousted from this relationship by other drugs.

    Data in vitro evidence that decitabine is a weak substratum for P-gp and therefore, most likely, is not subject to interaction with its inhibitors.

    Effect of decitabine on concomitant therapy:

    Since the binding of decitabine to blood plasma proteins in vitro extremely low (<1%), it is unlikely that it will displace protein-bound drugs.

    Studies conducted in vitro, showed that decitabine Does not inhibit or induce isoenzymes of the family CYP 450 up to a concentration in the plasma more than 20 times higher than the maximum observed in clinical conditions (CmOh). Therefore, it is not expected to be mediated through CYP 450 drug interactions, and interaction with other drugs metabolized through these metabolic pathways is unlikely.

    Decitabine is a weak inhibitor mediated through P-gp transport in vitro, and therefore can hardly influence the mediated through P-gp transport of other drugs (see section "Pharmacological properties").

    Incompatibility:

    In the absence of special studies of incompatibility, this drug should not be mixed with other drugs. Dacogen can not be administered via one intravenous catheter with other drugs.

    Special instructions:

    Myelosuppression

    Dacogen can strengthen the existing in patients with MDS and OML myelosuppression and its effects, including infections and bleeding. The myelosuppression caused by the Dacogen preparation is reversible. It should be done regularly, before each treatment cycle, and according to the indications, a complete clinical blood test, including platelets, should be performed. In the presence of myelosuppression or its complications, the use of the Dacogen drug may be suspended, the dose may be reduced or supportive measures may be taken as described in the "Dosage and Administration" and "Pharmacological properties" sections.

    Liver failure

    The possibility of using Dakogen in patients with hepatic insufficiency is not established. Care should be taken when prescribing Dakogen

    patients with hepatic insufficiency. You should carefully monitor these patients.

    Renal insufficiency

    The possibility of using Dakogen in patients with severe renal failure has not been studied. Care should be taken when using the drug in patients with severe renal insufficiency (creatinine clearance <30 ml / min), and carefully monitor them.

    Heart Disease

    Patients with heart disease, with severe congestive heart failure in history or with heart disease in the decompensated stage were not included in the clinical studies, so the safety and efficacy of Dakogen in these patients is not established.

    Application in men

    During the treatment period and within 3 months after discontinuation of treatment with Dacogen, men are recommended to use adequate contraception, since decitabine violates their reproductive function and has a mutagenic effect.Because of the possibility of developing infertility as a result of the use of Dakogen, men are advised to get advice about the possibility of preserving sperm before starting treatment.

    Application in children:

    Safety and efficacy of the drug in children are not established.

    Excipients

    1 bottle of the drug contains 0.5 mmol of potassium. After preparation, the infusion solution contains 1 to 10 millimoles of potassium per 1 dose, depending on the type of infusion solution used for dilution. This information should be taken into account by patients with reduced renal function and patients on a diet with control of the amount of potassium.

    1 bottle of the drug contains 0.29 mmol of sodium. After preparation, the infusion solution contains 0.6 to 6 millimoles of sodium per dose, depending on the type of infusion solution used for dilution. This information should be taken into account by patients on a diet that controls the amount of sodium.

    Effect on the ability to drive transp. cf. and fur:Studies of the effect of decitabine on the ability to drive by other mechanisms have not been carried out.If, during treatment, the patient develops side effects, such as anemia or associated symptoms: weakness, fatigue, dizziness, caution should be advised when driving the car and the mechanisms.
    Form release / dosage:
    Liofilizate for the preparation of concentrate for the preparation of a solution for infusions of 50 mg.
    Packaging:
    For 129.6 mg of the drug (corresponding to 50 mg of decitabine) in a 20 ml glass vial of capacity with a bromobutyl rubber stopper, coated with an aluminum lid. One bottle is packed in a glyco-modified polyethylene terephthalate blister, covered with foil made of Taiwec material. 1 blister is placed in a cardboard box together with instructions for medical use.
    Storage conditions:
    At a temperature of no higher than 25 ° C.
    After dissolution:
    If the infusion solution is not supposed to be administered within 15 minutes after preparation, the lyophilizate must be dissolved with a cold infusion solution; The solution prepared in this way can be stored at a temperature of 2 to 8 ° C not more than 4 hours before the introduction.
    Keep out of the reach of children.
    Shelf life:3 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-002442
    Date of registration:30.11.2011
    Expiration Date:Unlimited
    The owner of the registration certificate:Johnson & Johnson, LLC Johnson & Johnson, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.03.2017
    Illustrated instructions
      Instructions
      Up